@article{f8433d0c83e44afb97bdafbcb1d98e51,
title = "Effect of Postoperative Oral Intake Status on Sarcopenia Six Months After Esophageal Cancer Surgery",
abstract = "Purpose: In patients with esophageal cancer, skeletal muscle mass has been reported to decrease progressively after surgery and be independently associated with a poor prognosis. The purpose of this study was to investigate perioperative changes in dysphagia, oral intake status, and nutritional status and identify factors related to sarcopenia 6 months after esophagectomy. Methods: A total of 134 patients who underwent radical resection for thoracic esophageal cancer between March 2016 and July 2019 were analyzed retrospectively. The diagnosis of sarcopenia was made by CT taken 6 months postoperatively using the cut-off criteria of skeletal muscle index (SMI) < 52.4 cm2/m2 for male and SMI < 38.5 cm2/m2 for female patients. As factors related to postoperative sarcopenia, dysphagia, oral intake status, nutritional status, and physical function were extracted from the medical records. Multivariate logistic regression analysis was performed to identify perioperative risk factors related to sarcopenia 6 months after surgery. Results: Of the 134 patients, 34.3% were judged to be unable to start oral intake on swallowing assessment. At discharge, 30.6% received tube feeding with or without oral intake. In the non-oral intake group on swallowing assessment, a significantly higher proportion of patients received tube feeding at discharge (p = 0.014). Preoperative BMI, postoperative handgrip strength, and tube feeding at discharge were independent risk factors for sarcopenia 6 months after esophagectomy in male patients. Conclusion: Tube feeding at discharge is significantly related to postoperative sarcopenia in patients with esophageal cancer. Identifying high-risk groups might allow early detection of malnutrition and provision of appropriate care.",
keywords = "Dysphagia, Esophageal cancer, Esophagectomy, Oral intake, Sarcopenia, Videofluoroscopy",
author = "Nanako Hijikata and Aiko Ishikawa and Satoru Matsuda and Michiyuki Kawakami and Kaori Muraoka and Makiko Ando and Shuhei Mayanagi and Tomoyuki Irino and Hirofumi Kawakubo and Yuko Kitagawa and Tetsuya Tsuji",
note = "Funding Information: The authors would like to thank Ryota Ishii at Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital (current affiliation: Department of Biostatistics, Faculty of Medicine, University of Tsukuba) for assistance with this project. Funding Information: Dr. Kitagawa reports grants and personal fees from ASAHI KASEI PHARMA CORPORATION, grants and personal fees from TAIHO PHARMACEUTICAL CO., LTD, grants and personal fees from CHUGAI PHARMACEUTICAL CO., LTD., grants and personal fees from EA Pharma Co., Ltd., grants and personal fees from Yakult Honsha Co. Ltd., grants and personal fees from Otsuka Pharmaceutical Co., Ltd., grants from Takeda Pharmaceutical Co., Ltd., grants and personal fees from Otsuka Pharmaceutical Factory Inc., grants from KAKEN PHARMACEUTICAL CO.,LTD., grants and personal fees from Astellas Pharma Inc., grants from MEDICON INC., grants and personal fees from DAINIPPON SUMITOMO PHARMA Co., Ltd., grants and personal fees from Toyama Chemical Co., Ltd., grants from Kyouwa Hakkou Kirin Co., Ltd., grants and personal fees from ONO PHARMACEUTICAL CO., LTD., grants and personal fees from NIHON PHARMACEUTICAL CO., LTD., grants from TSUMURA & CO., grants from Nippon Covidien Inc., grants from Eisai Co., Ltd., grants from TEIJIN PHARMA LIMITED., personal fees from SHIONOGI & CO., LTD., personal fees from Bristol-Myers Squibb K.K., outside the submitted work. The other authors declare that they have no conflict of interest. Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2023",
month = feb,
doi = "10.1007/s00455-022-10471-z",
language = "English",
volume = "38",
pages = "340--350",
journal = "Dysphagia",
issn = "0179-051X",
publisher = "Springer New York",
number = "1",
}